Novartis AG (LON:0K9E)

Market Cap	188.41B
Revenue (ttm)	41.94B
Net Income (ttm)	10.71B
Shares Out	n/a
EPS (ttm)	5.43
PE Ratio	17.60
Forward PE	15.01
Dividend	2.61 (2.00%)
Ex-Dividend Date	Mar 12, 2025

Volume	1,405
Average Volume	11,722
Open	130.26
Previous Close	129.83
Day's Range	129.76 - 131.25
52-Week Range	96.11 - 134.00
Beta	n/a
RSI	54.20
Earnings Date	Feb 4, 2026

About Novartis AG

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocy...

• Industry: Pharmaceutical Preparations
• Founded: 1996
• Employees: 75,883
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0K9E

Financial Performance

In 2024, Novartis AG's revenue was $51.72 billion, an increase of 10.85% compared to the previous year's $46.66 billion. Earnings were $11.94 billion, a decrease of -19.59%.

Financial numbers in USD